Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus VARDENAFIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus VARDENAFIL HYDROCHLORIDE.
ATMEKSI vs VARDENAFIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum, thereby facilitating penile erection.
1.5 mg/kg IV every 4 weeks
10 mg orally once daily as needed, approximately 60 minutes before sexual activity; maximum dose 20 mg; maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life is approximately 4-5 hours in healthy subjects. In elderly patients (≥65 years) or those with hepatic impairment (Child-Pugh A/B), half-life may be prolonged up to 6-8 hours.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Primarily hepatic metabolism (CYP3A4, minor CYP2C9) followed by fecal excretion (approximately 91-95% of dose as metabolites) and renal excretion (approximately 2-6% as unchanged drug).
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor